https://www.gov.uk/government/groups/scientific-advisory-committee-on-nutrition#reports<\/a><\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
}
, "answeringMemberConstituency" : {"_value" : "Winchester"}
, "answeringMemberPrinted" : {"_value" : "Steve Brine"}
, "dateOfAnswer" : {"_value" : "2018-07-04", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2018-07-04T14:45:38.78Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2018-06-27", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Scientific Advisory Committee On Nutrition"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 4 June 2018 to Question 147850 on Scientific Advisory Committee on Nutrition, what need was identified (a) through horizon scanning and (b) at the request of government for each nutritional risk assessment carried out in each of the last five years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1533", "label" : {"_value" : "Biography information for Dame Diana Johnson"}
}
, "tablingMemberConstituency" : {"_value" : "Kingston upon Hull North"}
, "tablingMemberPrinted" : [{"_value" : "Diana Johnson"}
], "uin" : "158195"}
, {"_about" : "http://data.parliament.uk/resources/931990", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/931990/answer", "answerText" : {"_value" : "There are no current plans to request advice from the Scientific Advisory Committee on Nutrition on how malnutrition in the general population can be tackled.<\/p>
<\/p>
The National Diet and Nutrition Survey (NDNS) collects information on diet and nutrient intakes and nutritional status but does not assess the prevalence of malnutrition in the population. Malnutrition is a complex, multifactorial condition which develops over a period of time, and for which there is no single agreed medical definition. NDNS assesses an individual\u2019s diet and nutritional status at a single point in time and cannot assess other factors associated with malnutrition such as weight loss, or malabsorption of nutrients due to disease. It is therefore not possible to classify individuals as malnourished solely from the data collected in NDNS.<\/p>
<\/p>
Data from the National Diet and Nutrition Survey collected between 2008 and 2016 shows that nutrient intakes have changed relatively little over this period with the exception of free sugars and salt.<\/p>
<\/p>
Mean intakes of free sugars for adults (19-64 years) and children (4-10 and 11-18 years) were significantly lower in 2014/16 than in 2008/10 though remained more than double the recommended maximum in all age groups. Mean salt intake in adults, assessed through urinary sodium surveys, was 11% lower in 2014 than in 2006 but also remained above the recommended maximum. Mean intakes of fibre in children were significantly lower in 2014/16 than in 2008/10 and were below the recommendation. There were no consistent trends in intakes of total or saturated fat, total carbohydrate, or for vitamins or minerals.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
}
, "answeringMemberConstituency" : {"_value" : "Winchester"}
, "answeringMemberPrinted" : {"_value" : "Steve Brine"}
, "dateOfAnswer" : {"_value" : "2018-07-04", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2018-07-04T14:44:16.467Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2018-06-27", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Scientific Advisory Committee On Nutrition"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 4 June 2018 to Question 147851, what recent assessment he has made of trends in the level of (a) malnutrition and (b) nutrition intake in the general population as set out in the National Diet and Nutrition Survey; and if he will make (i) it his policy to request advice from the Scientific Advisory Committee on Nutrition on how malnutrition in the general population can be tackled and (ii) a statement.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1533", "label" : {"_value" : "Biography information for Dame Diana Johnson"}
}
, "tablingMemberConstituency" : {"_value" : "Kingston upon Hull North"}
, "tablingMemberPrinted" : [{"_value" : "Diana Johnson"}
], "uin" : "158196"}
, {"_about" : "http://data.parliament.uk/resources/931265", "AnsweringBody" : [{"_value" : "Foreign and Commonwealth Office"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/931265/answer", "answerText" : {"_value" : "The Government remains deeply concerned by the reported human rights abuses and excessive use of force by security services. We condemn violence against peaceful protesters, particularly the use of live ammunition. The Nicaraguan Government must respect human rights and take responsibility for ending the violence."}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/343", "label" : {"_value" : "Biography information for Sir Alan Duncan"}
}
, "answeringMemberConstituency" : {"_value" : "Rutland and Melton"}
, "answeringMemberPrinted" : {"_value" : "Sir Alan Duncan"}
, "dateOfAnswer" : {"_value" : "2018-06-26", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2018-06-26T15:06:59.317Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "16"}
, "answeringDeptShortName" : {"_value" : "Foreign and Commonwealth Office"}
, "answeringDeptSortName" : {"_value" : "Foreign and Commonwealth Office"}
, "date" : {"_value" : "2018-06-26", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Nicaragua: Human Rights"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "What recent assessment he has made of the human rights situation in Nicaragua.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1533", "label" : {"_value" : "Biography information for Dame Diana Johnson"}
}
, "tablingMemberConstituency" : {"_value" : "Kingston upon Hull North"}
, "tablingMemberPrinted" : [{"_value" : "Diana Johnson"}
], "uin" : "906056"}
, {"_about" : "http://data.parliament.uk/resources/928003", "AnsweringBody" : [{"_value" : "Northern Ireland Office"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/928003/answer", "answerText" : {"_value" : "
The Government has no plans to amend the law on abortion in either England and Wales or Northern Ireland.<\/p>
<\/p>
Abortion has always been a devolved matter in Northern Ireland. The Government's priority is therefore restoring devolved government, so that the people of Northern Ireland, and locally elected representatives, can decide what is right for Northern Ireland.<\/p>
<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4110", "label" : {"_value" : "Biography information for Dame Karen Bradley"}
}
, "answeringMemberConstituency" : {"_value" : "Staffordshire Moorlands"}
, "answeringMemberPrinted" : {"_value" : "Karen Bradley"}
, "dateOfAnswer" : {"_value" : "2018-06-27", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2018-06-27T14:40:22.473Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "21"}
, "answeringDeptShortName" : {"_value" : "Northern Ireland"}
, "answeringDeptSortName" : {"_value" : "Northern Ireland"}
, "date" : {"_value" : "2018-06-20", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Offences against the Person Act 1861: Northern Ireland"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Northern Ireland, whether she will exercise her power under section 26(2) of the Northern Ireland Act 1998 to repeal sections 58 and 59 of the Offences Against the Person Act 1861 in order to comply with the UK's international obligations under the United Nations Convention on the Elimination of All Forms of Discrimination against Women.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1533", "label" : {"_value" : "Biography information for Dame Diana Johnson"}
}
, "tablingMemberConstituency" : {"_value" : "Kingston upon Hull North"}
, "tablingMemberPrinted" : [{"_value" : "Diana Johnson"}
], "uin" : "155724"}
, {"_about" : "http://data.parliament.uk/resources/928004", "AnsweringBody" : [{"_value" : "Department for Business, Energy and Industrial Strategy"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/928004/answer", "answerText" : {"_value" : "
Sector Deals are a new approach to the way Government works in partnership with industry to improve the productivity of their sector. Since the publication of the Industrial Strategy, four Deals have already been announced and there are more in discussion.<\/p>
<\/p>
Several sectors, including those in the clean energy sector, have expressed interest in a Sector Deal and we expect to progress with further Deals that best meet the expectations set out in the White Paper in due course.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/3974", "label" : {"_value" : "Biography information for Claire Perry"}
}
, "answeringMemberConstituency" : {"_value" : "Devizes"}
, "answeringMemberPrinted" : {"_value" : "Claire Perry"}
, "dateOfAnswer" : {"_value" : "2018-06-27", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2018-06-27T16:33:43.337Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "201"}
, "answeringDeptShortName" : {"_value" : "Business, Energy and Industrial Strategy"}
, "answeringDeptSortName" : {"_value" : "Business, Energy and Industrial Strategy"}
, "date" : {"_value" : "2018-06-20", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Energy: Environment Protection"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Business, Energy and Industrial Strategy, what the timetable is for his Department to publish the Clean Energy Sector Deal.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1533", "label" : {"_value" : "Biography information for Dame Diana Johnson"}
}
, "tablingMemberConstituency" : {"_value" : "Kingston upon Hull North"}
, "tablingMemberPrinted" : [{"_value" : "Diana Johnson"}
], "uin" : "155725"}
, {"_about" : "http://data.parliament.uk/resources/926654", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/926654/answer", "answerText" : {"_value" : "
Extended Half Life products are relatively new products for which data is maturing and is collected via the UK Haemophilia database. These products provide an appropriate treatment for some patients.<\/p>
<\/p>
NHS England, through the Commercial Medicines Unit (CMU), undertakes national tenders which allow all companies who produce plasma, recombinant and extended half-life products to submit prices to be included in the national pricing framework. The relative prices are used to determine commissioning access for all products, including extended half-life products.<\/p>
<\/p>
Through commissioning processes such as the Haemophilia Quality Dashboard, patient experience of treatment and its outcomes in relation to bleeds and joint scores is kept regularly under review. The opportunity to continuously improve the patient experience and value of treatment with similar or improved clinical outcomes is an area for further assessment based on new and emerging data.<\/p>
<\/p>
There are a number of new therapeutic agents for haemophilia, including extended half-life products, and many patients are being recruited to clinical trials or early access schemes for new products. When assessing tenders for haemophilia products, NHS England takes into account the clinical outcomes to be achieved, the data available on the products and the prices offered. The aim is to deliver access to a range of treatments to meet individual patient need whilst supporting the use of clinically appropriate lowest cost options to achieve the outcomes required. This process has delivered both access to new treatments and substantial savings. No review of the tendering process is planned.<\/p>
<\/p>
NHS England regularly reviews its tender framework for blood products to ensure a range of treatments are commissioned to meet individual patient and maximises the use of clinically appropriate lowest cost options to achieve the clinical outcomes required.<\/p>
<\/p>
An assessment of comparative uptake compared to the uptake in Ireland, Canada and the European Union has not been undertaken.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
}
, "answeringMemberConstituency" : {"_value" : "Winchester"}
, "answeringMemberPrinted" : {"_value" : "Steve Brine"}
, "dateOfAnswer" : {"_value" : "2018-06-26", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : [{"_value" : "154638"}
, {"_value" : "154639"}
, {"_value" : "154640"}
], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2018-06-26T15:35:39.243Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2018-06-18", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Haemophilia: Medical Treatments"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps the Government is taking to increase the uptake of extended half life treatment by people with (a) haemophilia A and (b) haemophilia B.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1533", "label" : {"_value" : "Biography information for Dame Diana Johnson"}
}
, "tablingMemberConstituency" : {"_value" : "Kingston upon Hull North"}
, "tablingMemberPrinted" : [{"_value" : "Diana Johnson"}
], "uin" : "154637"}
, {"_about" : "http://data.parliament.uk/resources/926655", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/926655/answer", "answerText" : {"_value" : "
Extended Half Life products are relatively new products for which data is maturing and is collected via the UK Haemophilia database. These products provide an appropriate treatment for some patients.<\/p>
<\/p>
NHS England, through the Commercial Medicines Unit (CMU), undertakes national tenders which allow all companies who produce plasma, recombinant and extended half-life products to submit prices to be included in the national pricing framework. The relative prices are used to determine commissioning access for all products, including extended half-life products.<\/p>
<\/p>
Through commissioning processes such as the Haemophilia Quality Dashboard, patient experience of treatment and its outcomes in relation to bleeds and joint scores is kept regularly under review. The opportunity to continuously improve the patient experience and value of treatment with similar or improved clinical outcomes is an area for further assessment based on new and emerging data.<\/p>
<\/p>
There are a number of new therapeutic agents for haemophilia, including extended half-life products, and many patients are being recruited to clinical trials or early access schemes for new products. When assessing tenders for haemophilia products, NHS England takes into account the clinical outcomes to be achieved, the data available on the products and the prices offered. The aim is to deliver access to a range of treatments to meet individual patient need whilst supporting the use of clinically appropriate lowest cost options to achieve the outcomes required. This process has delivered both access to new treatments and substantial savings. No review of the tendering process is planned.<\/p>
<\/p>
NHS England regularly reviews its tender framework for blood products to ensure a range of treatments are commissioned to meet individual patient and maximises the use of clinically appropriate lowest cost options to achieve the clinical outcomes required.<\/p>
<\/p>
An assessment of comparative uptake compared to the uptake in Ireland, Canada and the European Union has not been undertaken.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
}
, "answeringMemberConstituency" : {"_value" : "Winchester"}
, "answeringMemberPrinted" : {"_value" : "Steve Brine"}
, "dateOfAnswer" : {"_value" : "2018-06-26", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : [{"_value" : "154637"}
, {"_value" : "154639"}
, {"_value" : "154640"}
], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2018-06-26T15:35:39.337Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2018-06-18", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Haemophilia: Medical Treatments"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, whether NHS England has made an assessment of (a) the potential merits of reducing the number of infusions of blood products, (b) improvements in health-related quality of life, (c) improved Haemophilia Joint Health scores and (d) reductions in Annual Bleeding Rates in decision-making on the procurement of haemophilia treatments; and if he will make an assessment of the effectiveness of NHS England\u2019s tendering process for haemophilia treatment.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1533", "label" : {"_value" : "Biography information for Dame Diana Johnson"}
}
, "tablingMemberConstituency" : {"_value" : "Kingston upon Hull North"}
, "tablingMemberPrinted" : [{"_value" : "Diana Johnson"}
], "uin" : "154638"}
, {"_about" : "http://data.parliament.uk/resources/926656", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/926656/answer", "answerText" : {"_value" : "
Extended Half Life products are relatively new products for which data is maturing and is collected via the UK Haemophilia database. These products provide an appropriate treatment for some patients.<\/p>
<\/p>
NHS England, through the Commercial Medicines Unit (CMU), undertakes national tenders which allow all companies who produce plasma, recombinant and extended half-life products to submit prices to be included in the national pricing framework. The relative prices are used to determine commissioning access for all products, including extended half-life products.<\/p>
<\/p>
Through commissioning processes such as the Haemophilia Quality Dashboard, patient experience of treatment and its outcomes in relation to bleeds and joint scores is kept regularly under review. The opportunity to continuously improve the patient experience and value of treatment with similar or improved clinical outcomes is an area for further assessment based on new and emerging data.<\/p>
<\/p>
There are a number of new therapeutic agents for haemophilia, including extended half-life products, and many patients are being recruited to clinical trials or early access schemes for new products. When assessing tenders for haemophilia products, NHS England takes into account the clinical outcomes to be achieved, the data available on the products and the prices offered. The aim is to deliver access to a range of treatments to meet individual patient need whilst supporting the use of clinically appropriate lowest cost options to achieve the outcomes required. This process has delivered both access to new treatments and substantial savings. No review of the tendering process is planned.<\/p>
<\/p>
NHS England regularly reviews its tender framework for blood products to ensure a range of treatments are commissioned to meet individual patient and maximises the use of clinically appropriate lowest cost options to achieve the clinical outcomes required.<\/p>
<\/p>
An assessment of comparative uptake compared to the uptake in Ireland, Canada and the European Union has not been undertaken.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
}
, "answeringMemberConstituency" : {"_value" : "Winchester"}
, "answeringMemberPrinted" : {"_value" : "Steve Brine"}
, "dateOfAnswer" : {"_value" : "2018-06-26", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : [{"_value" : "154637"}
, {"_value" : "154638"}
, {"_value" : "154640"}
], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2018-06-26T15:35:39.433Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2018-06-18", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Haemophilia: Medical Treatments"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what comparative assessment the Government has made of the uptake in England of extended half life treatment for people with (a) haemophilia A and (b) haemophilia B with the uptake of that treatment in (i) Ireland, (ii) Canada and (iii) the EU.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1533", "label" : {"_value" : "Biography information for Dame Diana Johnson"}
}
, "tablingMemberConstituency" : {"_value" : "Kingston upon Hull North"}
, "tablingMemberPrinted" : [{"_value" : "Diana Johnson"}
], "uin" : "154639"}
, {"_about" : "http://data.parliament.uk/resources/926657", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/926657/answer", "answerText" : {"_value" : "
Extended Half Life products are relatively new products for which data is maturing and is collected via the UK Haemophilia database. These products provide an appropriate treatment for some patients.<\/p>
<\/p>
NHS England, through the Commercial Medicines Unit (CMU), undertakes national tenders which allow all companies who produce plasma, recombinant and extended half-life products to submit prices to be included in the national pricing framework. The relative prices are used to determine commissioning access for all products, including extended half-life products.<\/p>
<\/p>
Through commissioning processes such as the Haemophilia Quality Dashboard, patient experience of treatment and its outcomes in relation to bleeds and joint scores is kept regularly under review. The opportunity to continuously improve the patient experience and value of treatment with similar or improved clinical outcomes is an area for further assessment based on new and emerging data.<\/p>
<\/p>
There are a number of new therapeutic agents for haemophilia, including extended half-life products, and many patients are being recruited to clinical trials or early access schemes for new products. When assessing tenders for haemophilia products, NHS England takes into account the clinical outcomes to be achieved, the data available on the products and the prices offered. The aim is to deliver access to a range of treatments to meet individual patient need whilst supporting the use of clinically appropriate lowest cost options to achieve the outcomes required. This process has delivered both access to new treatments and substantial savings. No review of the tendering process is planned.<\/p>
<\/p>
NHS England regularly reviews its tender framework for blood products to ensure a range of treatments are commissioned to meet individual patient and maximises the use of clinically appropriate lowest cost options to achieve the clinical outcomes required.<\/p>
<\/p>
An assessment of comparative uptake compared to the uptake in Ireland, Canada and the European Union has not been undertaken.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
}
, "answeringMemberConstituency" : {"_value" : "Winchester"}
, "answeringMemberPrinted" : {"_value" : "Steve Brine"}
, "dateOfAnswer" : {"_value" : "2018-06-26", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : [{"_value" : "154637"}
, {"_value" : "154638"}
, {"_value" : "154639"}
], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2018-06-26T15:35:39.56Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2018-06-18", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Haemophilia: Medical Treatments"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, he will make it his policy to ensure that all eligible patients with (a) haemophilia A and (b) haemophilia B have access to extended half life blood treatments.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1533", "label" : {"_value" : "Biography information for Dame Diana Johnson"}
}
, "tablingMemberConstituency" : {"_value" : "Kingston upon Hull North"}
, "tablingMemberPrinted" : [{"_value" : "Diana Johnson"}
], "uin" : "154640"}
, {"_about" : "http://data.parliament.uk/resources/922049", "AnsweringBody" : [{"_value" : "Home Office"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/922049/answer", "answerText" : {"_value" : "
On 8 March we launched a 12 week public consultation on proposals for a landmark domestic abuse Bill and a supporting package of practical action to transform the response to domestic abuse. The consultation closed on 31 May. Over 3,200 responses to the consultation were received. The responses to the consultation are being considered and a draft Bill will be published later this session.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4399", "label" : {"_value" : "Biography information for Victoria Atkins"}
}
, "answeringMemberConstituency" : {"_value" : "Louth and Horncastle"}
, "answeringMemberPrinted" : {"_value" : "Victoria Atkins"}
, "dateOfAnswer" : {"_value" : "2018-06-14", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2018-06-14T16:28:07.817Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "1"}
, "answeringDeptShortName" : {"_value" : "Home Office"}
, "answeringDeptSortName" : {"_value" : "Home Office"}
, "date" : {"_value" : "2018-06-11", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Domestic Abuse"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for the Home Department, what the timetable is for his Department to respond to it's consultation on the draft Domestic Violence and Abuse Bill; and what the timetable is for further steps to be taken in relation to that Bill.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1533", "label" : {"_value" : "Biography information for Dame Diana Johnson"}
}
, "tablingMemberConstituency" : {"_value" : "Kingston upon Hull North"}
, "tablingMemberPrinted" : [{"_value" : "Diana Johnson"}
], "uin" : "152095"}
], "itemsPerPage" : 10, "next" : "https://eldaddp.azurewebsites.net/answeredquestions.text?tablingMember.label=Biography+information+for+Dame+Diana+Johnson&_page=1&max-ddpModified.=2018-07-05T14%3A35%3A04.889Z", "page" : 0, "startIndex" : 1, "totalResults" : 1397, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}